SC

Shaan C. Gandhi

Head of Strategic Partnerships, Pfizer Ignite

Cambridge, Massachusetts

Investor
VC

Invests in

  • Min Investment:

    $100,000.00

  • Max Investment:

    $5,000,000.00

  • Target Investment:

    $1,500,000.00

Skills

Medicine
Healthcare Information Technology
Healthcare
Cancer Research
Data Analysis
Public Speaking
Clinical Research
Oncology
Health Policy
Strategy
Public Policy
Health Insurance
Internal Medicine
Clinical Trials
Informatics
Biotechnology
Managed Care
Entrepreneurship
Venture Capital
Healthcare Information Technology (HIT)

Education

Investments

Kyverna Therapeutics

Series B

Total Funding: $170M

Opna Bio

Series A

Total Funding: $38M

CAMP4 Therapeutics

Series A

Total Funding: $180M

Transition Bio

Series A

Total Funding: $50M

Triumvira Immunologics

Series A

Total Funding: $100M

Garuda Therapeutics

Series A

Total Funding: $130M

StrideBio

Series B

Total Funding: $98M

Work Experience

Pfizer

2023

  • Vice President and Head of Strategic Partnerships, Pfizer Ignite

    2023

    Pfizer Ignite is a new end-to-end offering for biotech partners that leverages Pfizer’s resources, scale and expertise to amplify and accelerate innovation from preclinical R&D through the development lifecycle. Learn more at www.pfizerignite.com.

1910 Genetics

2023

  • Independent Board Member

    2023

DICE Therapeutics

2020 - 2023

  • Board Member

    2020 - 2023

    Acquired by Eli Lilly (NYSE: LLY) August 2023, formerly NASDAQ: DICE

Vigil Neuroscience

2020 - 2023

  • Board Member

    2020 - 2023

    NASDAQ: VIGL

Kyverna Therapeutics

2022 - 2022

  • Board Member

    2022 - 2022

    NASDAQ: KYTX

Transition Bio, Inc.

2022 - 2022

  • Board Member

    2022 - 2022

StrideBio, Inc

2021 - 2022

  • Board Member

    2021 - 2022

CAMP4 Therapeutics

2021 - 2022

  • Board Member

    2021 - 2022

Mestag Therapeutics

2021 - 2022

  • Board Member

    2021 - 2022

Garuda Therapeutics

2021 - 2022

  • Board Member

    2021 - 2022